

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 November 2022 (10.11.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/235933 A8



(51) International Patent Classification:

A61K 48/00 (2006.01) C07K 14/435 (2006.01)
A61P 27/16 (2006.01)

(21) International Application Number:

PCT/US2022/027870

(22) International Filing Date:

05 May 2022 (05.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/184,737 05 May 2021 (05.05.2021) US

(71) Applicant: **DECIBEL THERAPEUTICS, INC.**
[US/US]; 1325 Boylston Street, Suite 500, Boston, MA
02215 (US).

(72) Inventors: **BURNS, Joseph**; 1325 Boylston Street, Suite
500, Boston, MA 02215 (US). **SCHWANDER, Martin**;

1325 Boylston Street, Suite 500, Boston, MA 02215 (US).
WU, XuDong; 1325 Boylston Street, Suite 500, Boston,
MA 02215 (US). **BECKER, Lars**; 1325 Boylston Street,
Suite 500, Boston, MA 02215 (US). **GIBSON, Tyler**; 1325
Boylston Street, Suite 500, Boston, MA 02215 (US). **PAN,**
Ning; 1325 Boylston Street, Suite 500, Boston, MA 02215
(US).

(74) Agent: **BELLIVEAU, Michael, J.**; CLARK & ELBING
LLP, 101 Federal Street, 15th Floor, Boston, MA 02110
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,

(54) Title: COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING STEREOCILIN
DUAL VECTOR SYSTEMS

FIG. 1A



(57) Abstract: The disclosure provides compositions containing polynucleotides that encode a stereocilin protein under regulatory control of an outer hair cell-specific promoter, as well as two-vector systems containing the same, that can be used to promote expression of stereocilin specifically in outer hair cells. Additionally, the compositions described herein may be used for the treatment of subjects having or at risk of developing hearing loss, such as hearing loss associated with a mutation in stereocilin.

[Continued on next page]



WO 2022/235933 A8

NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:
29 December 2022 (29.12.2022)

(48) Date of publication of this corrected version:
02 February 2023 (02.02.2023)

(15) Information about Correction:
see Notice of 02 February 2023 (02.02.2023)